Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

NCT00005970 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3436

Enrollment

NIH

Sponsor class

Conditions

Breast Adenocarcinoma
HER2 Positive Breast Carcinoma
Stage IA Breast Cancer AJCC v7
Stage IB Breast Cancer AJCC v7
Stage IIA Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IIIA Breast Cancer AJCC v7

Interventions

DRUG: Aromatase Inhibition Therapy
DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel
DRUG: Tamoxifen Citrate
BIOLOGICAL: Trastuzumab

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]